Claims for Patent: 9,833,429

Summary for Patent: 9,833,429

Title:	Therapeutic compositions
Abstract:	Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.
Inventor(s):	Brown; Marc Barry (Watford, GB), Crothers; Michael Edward Donald (Hillsborough, GB), Nazir; Tahir (Middlesex, GB)
Assignee:	LEO Laboratories Limited (Dublin, IE)
Application Number:	15/163,295
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,833,429
Patent Claims:	1. A formulation, comprising: ingenol angelate, at least about 95% of the ingenol angelate being ingenol-3-angelate (isoform `b`); a penetration enhancer; a gelling agent; an acidifying agent; and a pharmaceutically acceptable solvent, wherein the formulation is a topical formulation and comprises ingenol-3-angelate (isoform `b`) in an amount from 0.001% by weight to 0.15% by weight. 2. The formulation of claim 1, wherein the solvent is selected from the group consisting of polyethylene glycol, methyl ethyl ketone, ethyl acetate, diethyl ether, and benzyl alcohol. 3. The formulation of claim 2, wherein the solvent is benzyl alcohol. 4. The formulation of claim 3, wherein the formulation comprises 0.9% by weight benzyl alcohol. 5. The formulation of claim 1, wherein the formulation has a pH of no greater than 4.5. 6. The formulation of claim 1, wherein the formulation has a pH of no less than 2.5. 7. The formulation of claim 1, wherein ingenol-3-angelate (isoform `b`) is the only active ingredient. 8. The formulation of claim 1, wherein the formulation is selected from the group consisting of a gel, a cream, an ointment, a paint, a lotion, and a foam. 9. The formulation of claim 1, wherein the formulation is suitable for storage at 2-8.degree. C. 10. The formulation of claim 1, wherein the formulation is suitable for storage at 2-8.degree. C. for at least one year. 11. A formulation, comprising: ingenol-3-angelate (isoform `b`); isopropyl alcohol; hydroxyethylcellulose; benzyl alcohol; an acid buffer comprising citric acid and sodium citrate; and water; wherein the formulation is a topical formulation and comprises ingenol-3-angelate (isoform `b`) in an amount from 0.001% by weight to 0.15% by weight. 12. The formulation of claim 11, wherein the formulation comprises from 0.01% by weight to 0.1% by weight ingenol-3-angelate (isoform `b`). 13. The formulation of claim 11, wherein the formulation comprises 30% by weight isopropyl alcohol. 14. The formulation of claim 11, wherein the formulation comprises from 1% by weight to 5% by weight hydroxyethylcellulose. 15. The formulation of claim 11, wherein the formulation comprises 0.9% by weight benzyl alcohol. 16. The formulation of claim 11, wherein the formulation comprises from 0.5% by weight to 10% by weight acid buffer. 17. The formulation of claim 11, wherein the formulation comprises: from 0.001% by weight to 0.15% by weight ingenol-3-angelate (isoform `b`); 30% by weight isopropyl alcohol; 1.5% by weight hydroxyethylcellulose; 0.9% by weight benzyl alcohol; from 0.5% by weight to 10% by weight acid buffer; and water. 18. The formulation of claim 11, wherein the formulation has a pH of no greater than 4.5. 19. The formulation of claim 11, wherein the formulation has a pH of no less than 2.5. 20. The formulation of claim 11, wherein ingenol-3-angelate (isoform `b`) is the only active ingredient. 21. The formulation of claim 11, wherein the formulation is selected from the group consisting of a gel, a cream, an ointment, a paint, a lotion, and a foam. 22. The formulation of claim 11, wherein the formulation is suitable for storage at 2-8.degree. C. 23. The formulation of claim 11, wherein the formulation is suitable for storage at 2-8.degree. C. for at least one year. 24. The formulation of claim 1, wherein at least about 99% of the ingenol angelate is ingenol-3-angelate (isoform `b`).